Conditions: Healthy Volunteers
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 56
Healthy volunteers: yes

Brief summary:
The purpose of this study is to investigate the safety and tolerability of LY3016859 administered as single doses, and to determine how long LY3016859 remains in the body

Detailed description:

Arms:
arm 1: Placebo administered once intravenously arm 2: 0.1 mg LY3016859 administered once intravenously arm 3: 1 mg LY3016859 administered once intravenously arm 4: 10 mg LY3016859 administered once intravenously arm 5: 50 mg LY3016859 administered once intravenously arm 6: 250 mg LY3016859 administered once intravenously arm 7: 750 mg LY3016859 administered once intravenously arm 8: Placebo administered once subcutaneously arm 9: 50 mg LY3016859 administered once subcutaneously

Interventions: intervention 1: LY3016859 intravenous intervention 2: Placebo intravenous intervention 3: LY3016859 subcutaneous intervention 4: Placebo subcutaneous
Intervention descriptions: intervention 1: Administered intravenously intervention 2: Administered intravenously intervention 3: Administered subcutaneously intervention 4: Administered subcutaneously

Protocol document: